1,6-디옥세케인 화합물과 이의 제조방법
    42.
    发明公开
    1,6-디옥세케인 화합물과 이의 제조방법 失效
    1,6-二氧化物及其制备方法

    公开(公告)号:KR1020100134977A

    公开(公告)日:2010-12-24

    申请号:KR1020090053364

    申请日:2009-06-16

    Abstract: PURPOSE: A method for preparing 1,6-dioxecane compound is provided to enlarge other ring by Diels-Alder reaction and to use as an intermediate. CONSTITUTION: A 1,6-Dioxecanes compound is denoted by chemical formula 1. The 1,6-Dioxecanes compound is prepared by Prins reaction of alcohol compound of chemical formula 2 and aldehyde compound of chemical formula 3. A tetrahydrofuran is used as a reaction catalyst. The reaction temperature is -78 to 30°C.

    Abstract translation: 目的:提供1,1-二氧化合物的制备方法,以通过狄尔斯 - 阿尔德反应扩大其它环并用作中间体。 构成:1,6-二氧癸烷化合物由化学式1表示。1,6-二氧癸烷化合物通过化学式2的醇化合物与化学式3的醛化合物的Prins反应制备。使用四氢呋喃作为反应 催化剂。 反应温度为-78〜30℃。

    1-(2-하이드록시페닐)부타-2-엔-1-온 또는 크로만-4-온 유도체의 제조방법
    45.
    发明授权
    1-(2-하이드록시페닐)부타-2-엔-1-온 또는 크로만-4-온 유도체의 제조방법 失效
    制备1-2-羟基苯基丁-2-烯-1-酮和色甘酸-4-酮的方法

    公开(公告)号:KR100935016B1

    公开(公告)日:2010-01-06

    申请号:KR1020080013153

    申请日:2008-02-13

    Abstract: 본 발명은 1-(2-하이드록시페닐)부타-2-엔-1-온 또는 크로만-4-온 유도체의 제조방법에 관한 것으로서, 더욱 상세하게는 2-에티이닐페놀 유도체를 루이스산 촉매 존재 하에서 알데하이드 화합물과 반응시켜 하기 화학식 1로 표시되는 1-(2-하이드록시페닐)부타-2-엔-1-온 유도체 또는 하기 화학식 2로 표시되는 크로만-4-온 유도체를 제조하는 방법에 관한 것이다.


    상기 화학식 1 또는 2에서, R
    1 및 R
    2 는 각각 발명의 상세한 설명에서 정의한 바와 같다.
    1-(2-하이드록시페닐)부타-2-엔-1-온, 크로만-4-온, 루이스산

    중추신경계 질환 치료제로 유효한N-벤질-N-(2-디메틸아미노-에틸)-벤젠술폰아미드 화합물
    46.
    发明授权
    중추신경계 질환 치료제로 유효한N-벤질-N-(2-디메틸아미노-에틸)-벤젠술폰아미드 화합물 失效
    使用N-苄基-N-(2-二甲基氨基 - 乙基)苯并呋喃衍生物治疗CNS病症

    公开(公告)号:KR100843351B1

    公开(公告)日:2008-07-03

    申请号:KR1020070009626

    申请日:2007-01-30

    CPC classification number: A61K31/18

    Abstract: An N-benzyl-N-(2-dimethylamino-ethyl)benzenesulfonamide compound is provided to show selective antagonistic activity on serotonin 5-HT2a or 5-HT2c receptor and have selective serotonin reuptake inhibitor(SSRI) activity, thereby being used for a pharmaceutical composition for treating and preventing central nervous system diseases. A pharmaceutical composition for treating and preventing diseases such as anxiety, depression, stroke, obsessive neurosis, psychosis, schizophrenia, suicidal tendency, sleep disorders, appetite disorders, withdrawal symptoms caused by drug abuse, and migraine comprises an N-benzyl-N-(2-dimethylamino-ethyl)benzenesulfonamide compound represented by a formula(1) or a pharmaceutically acceptable salt thereof. In the formula(1), R is H, halogen, hydroxy, C1-10 alkyl, C1-10 alkoxy, C1-10 haloalkyl, C1-10 haloalkoxy, C1-10 acyl, phenyl or phenyloxy, provided that a benzen-ring of the phenyl or the phenyloxy may be substituted by H, halogen, cyano, C1-10 alkyl or C1-10 alkoxy.

    Abstract translation: 提供N-苄基-N-(2-二甲基氨基 - 乙基)苯磺酰胺化合物以显示对5-羟色胺5-HT2a或5-HT2c受体的选择性拮抗活性,并且具有选择性5-羟色胺再摄取抑制剂(SSRI)活性,从而用于药物 用于治疗和预防中枢神经系统疾病的组合物。 用于治疗和预防诸如焦虑,抑郁,中风,强迫神经症,精神病,精神分裂症,自杀倾向,睡眠障碍,食欲障碍,药物滥用引起的戒断症状和偏头痛等疾病的药物组合物包含N-苄基-N-( 2-二甲基氨基 - 乙基)苯磺酰胺化合物或其药学上可接受的盐。 在式(1)中,R为H,卤素,羟基,C 1-10烷基,C 1-10烷氧基,C 1-10卤代烷基,C 1-10卤代烷氧基,C 1-10酰基,苯基或苯氧基,条件是苯环 的苯基或苯氧基可以被H,卤素,氰基,C 1-10烷基或C 1-10烷氧基取代。

    mGluR1 길항제로 작용하는 사이에노피리미디논 유도체
    50.
    发明公开
    mGluR1 길항제로 작용하는 사이에노피리미디논 유도체 有权
    三硝基嘧啶衍生物作为MGLUR1拮抗剂

    公开(公告)号:KR1020140101895A

    公开(公告)日:2014-08-21

    申请号:KR1020130014392

    申请日:2013-02-08

    CPC classification number: C07D495/04 A61K31/519

    Abstract: The present invention relates to thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as Parkinson′s disease and Alzheimer′s disease. The present invention also relates to methods for preparing the thienopyrimidinone derivatives, and pharmaceutical compositions containing the thienopyrimidinone derivatives as active ingredients.

    Abstract translation: 本发明涉及作为代谢型谷氨酸受体亚型1的拮抗剂的噻吩并嘧啶酮衍生物。噻吩并嘧啶酮衍生物显示针对代谢型谷氨酸受体相关疾病的药理学活性,包括疼痛,如神经性疼痛和偏头痛,精神疾病如焦虑障碍和 精神分裂症,尿失禁和神经变性疾病,如帕金森病和阿尔茨海默病。 本发明还涉及制备噻吩并嘧啶酮衍生物的方法和含有噻吩并嘧啶酮衍生物作为活性成分的药物组合物。

Patent Agency Ranking